Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study

Authors

Institutions

Publication Details

Journal
Pain and Therapy
Published
2025-12-11
DOI
https://doi.org/10.1007/s40122-025-00800-z
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study

Richard B. Lipton, Robert J. Fountaine, Linda Mosher
Pain and Therapy
Migraine and Headache Studies
article

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study

Richard B. Lipton, Robert J. Fountaine, Linda Mosher
article en

Abstract

No abstract available for this paper.
Pain and TherapyVol. 15(1)
Albert Einstein College of Medicine (US), Pfizer (United States) (US)
Pfizer
Openalex Percentile: Top 53%
Migraine and Headache Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study — Richard B. Lipton, Robert J. Fountaine, et al. · Pain and Therapy (2025) | TGRS Research Map | TGRS